The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...

The FDA has expanded its approval of talazoparib in combination with enzalutamide to include men with metastatic androgen ...

The new ASTRO guideline is based on a systematic review of evidence and expert opinion and includes recommendations for MHF, ...

A “life-changing” new approach to treating prostate cancer will be trialled in Tasmania. Urologist Dr Anthony Eaton will use ...

At ESMO 2026, experts forecast how RAS inhibitors, new prostate cancer therapies, and IO combinations may reshape pancreatic, ...

Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...

Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate ...

Adding darolutamide to standard treatment for aggressive prostate cancer reduced the risk of the disease spreading in an ...

Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr. Carlos ...

GLOBALLY, one in eight men will be diagnosed with prostate cancer during their lifetime, studies have shown.In African men, the risk is even higher - one out of every six men will develop the disease.